跳至主要内容
临床试验/NCT00131196
NCT00131196Unknown不适用

Functional Genomic Influences on Disease Progression and Outcome in Sepsis Due to Pneumonia or Peritonitis

University of Oxford49 个研究点 分布在 1 个国家目标入组 4,000 人开始时间: 2005年9月最近更新:
适应症

试验速览

阶段
不适用
入组人数
4,000
试验地点
49
主要终点
ICU and hospital Mortality

研究概览

简要总结

The proposal is aimed at identifying genetic factors that determine the incidence and severity of, and the outcome from life-threatening infections (severe sepsis/septic shock) in patients admitted to High Dependency Units (HDUs) or Intensive Care Units (ICUs) with pneumonia which developed outside the hospital (community acquired pneumonia - CAP) or contamination of the abdominal cavity with faeces due to a leak in the bowel (faecal peritonitis). This will require the acquisition of a large, high quality resource of genetic material (DNA), plasma, urine, white blood cells and clinical information from well characterized groups of similar patients with, or at risk for, severe sepsis/septic shock. The principal objective is to perform studies which are sufficiently large to establish beyond doubt the influence of a series of selected "candidate" genes on the development, progress and outcome of sepsis.

详细描述

The investigators plan to recruit 2,000 cases of community acquired pneumonia (CAP) and 2,000 cases of faecal peritonitis (FP) from 30 UK ICUs and HDUs (members of the UK Critical Care Genomics group - UKCCG). The large number of patients is required to satisfy the power calculations based upon the predicted allele frequencies of candidate genes and the level of functional expression of the gene polymorphisms.

If a patient is eligible, written, informed consent will be obtained either from the patient or, if the patient is incompetent via the patient's legal representative. Patients will be characterized clinically in terms of admission diagnosis, severity of illness (APACHE II), organ failures (SOFA) and final outcome (ICU and hospital mortality, death or survival 6 months following ICU admission. Date of death will be recorded when appropriate). Clinical status will be assessed daily for days 1, 2, 3, 5 and 7 of ICU admission using the Sepsis criteria, SOFA score, microbiological culture results and antibiotic therapy.

Selected ICUs will, following consent, also undertake blood and urine sampling on days 1, 3 and 5 for genomic, proteomic and metabolomic studies. Information will be recorded on a bar-coded paper clinical report form (CRF) at the bedside. The CRFs will be securely stored locally and copied to the research coordinator, where they will be archived. The data will be entered independently by the research coordinator and one of the investigators into a secure, central web-based electronic database for storage of clinical data and the calculation of derived values. The patient codes for genetic analysis will be derived directly from the clinical database. Those undertaking genotyping will be blinded to the clinical details and these two databases will be brought together at the time of analysis only under the direct supervision of one of the principal investigators.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient, or legal representative, is able to give informed consent
  • Male or female of 18 years or more
  • Patient admitted to ICU/HDU with faecal peritonitis or community acquired pneumonia

排除标准

  • Patient or legal representative is unwilling to consent
  • Patient is under the age of 18 years
  • Patient is already enrolled in an interventional study
  • Patient is immunocompromised
  • Patient is pregnant
  • There is an advance directive to withhold or withdraw life-sustaining treatment or patient is admitted for palliative care only.

结局指标

主要结局

ICU and hospital Mortality

时间窗: ICU discharge, hospital discharge and 6 month. The date of death will be recorded, as appropriate, for each patient.

次要结局

  • Severity of illness, duration of organ support, shock reversal, duration of ICU and hospital stay(From ICU admission to discharge)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr CS Garrard

Consultant in Intensive care

University of Oxford

研究点 (49)

Loading locations...

相似试验